NA Uterine Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,500	320 Pages	Data Bridge Market Research	January, 2023	DAABD17747057

Best Price Guarantee
Price	from $3,500
Length	320 Pages
Publisher	Data Bridge Market Research
Published Date	January, 2023
SKU	DAABD17747057

NA Uterine Cancer Diagnostics Market - Industry Trends and Forecast to 2030

North America Uterine Cancer Diagnostics Market, By Diagnostic Type (Instrument Based and Procedure Based), Type (Endometrial Cancer and Uterine Sarcoma), Age Group (<30, 31-40, 41-50, 51-60 And >60), End User (Hospitals, Diagnostic Centres, Cancer Research Centre, Ambulatory Surgical Centres, Specialized Clinics, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2030

Market Definition

Diagnosis of uterine cancer includes ultrasound, biopsy procedures, and blood tests. Ultrasound tests use sound waves and produce images of the ovaries and uterus. Two types of ultrasound are included in diagnostic testing for uterine cancer: abdominal ultrasound and transvaginal ultrasound. An abdominal scan test involves scanning the full bladder with a small probe across the abdomen, while a transvaginal scan involves inserting a probe tube into the vagina to scan or create an image. Biopsy procedures include endometrial biopsy, hysteroscopy, and dilation and curettage.

Cancer is one of the leading causes of death worldwide, and the prevalence of this disease has increased at an alarming rate. Therefore, health professionals are focusing on developing effective screening and treatment solutions to control obesity rates. Moreover, an endometrial biopsy involves removing some malignant tissue from the endometrium and sending it for a testing procedure. The growing number of geriatric women in the U.S. is also a major factor contributing to the growth of the uterine cancer diagnostic market.

Market Segmentation

The North America uterine cancer diagnostic market is segmented into five notable segments which are based on diagnostic type, type, age group, end user, and distribution channel.
• On the basis of diagnostic type, the North America uterine cancer diagnostic market is segmented into instrument based and procedure based
• On the basis of type, the North America uterine cancer diagnostic market is segmented into endometrial cancer and uterine sarcoma
• On the basis of age group, the North America uterine cancer diagnostic market is segmented into <30, 31-40, 41-50, 51-60, and >60
• On the basis of end user, the North America uterine cancer diagnostic market is segmented into hospitals, diagnostic centers, cancer research centers, ambulatory surgical centers, specialized clinics, and others
• On the basis of distribution channel, the North America uterine cancer diagnostic market is segmented into direct tender, third party distributors, and others

Market Players

Some of the major players operating in the North America uterine cancer diagnostic market are:
• F-Hoffmann La Roche Ltd.
• Siemens Healthcare Private Limited
• ESAOTE SPA
• Narang Medical Limited
• Olympus Corporation
• Integra LifeSciences
• KARL STORZ SE & Co. KG
• Stryker
• General Electric Company
• FUJIFILM Corporation
• Koninklijke Philips N.V.
• B. Braun SE
• AED.MD
• GRAIL

1 Introduction: 1.1 Objectives Of The Study; 1.2 Market Definition; 1.3 Overview Of The North America Uterine Cancer Diagnostic Market; 1.4 Currency And Pricing; 1.5 Limitations; 1.6 Markets Covered
2 Market Segmentation: 2.1 Markets Covered; 2.2 Geographical Scope; 2.3 Years Considered For The Study; 2.4 Dbmr Tripod Data Validation Model; 2.5 Primary Interviews With Key Opinion Leaders; 2.6 Multivariate Modelling; 2.7 Market Application Coverage Grid; 2.8 Instrument Based Lifeline Curve; 2.9 Dbmr Market Position Grid; 2.10 Vendor Share Analysis; 2.11 Secondary Sources; 2.12 Assumptions
3 Executive Summary
4 Premium Insights: 4.1 Pestel Analysis; 4.2 Porter’s Five Forces; 4.3 Patent Analysis Of North America Uterine Cancer Diagnostics Market; 4.4 Reimbursement Scenario; 4.5 Industry Insights:; 4.6 Demographic Trends: Impacts On All Incidence Rates; 4.7 Pricing Strategies; 4.8 Conclusion; 4.9 Prevalence, Incidence, And Mortality Rate Of Uterine Cancer; 4.10 Cost Of Uterine Cancer Procedure
5 Regulatory Framework
6 Market Overview: 6.1 Drivers; 6.1.1 Technological Advancements In Uterine Cancer Diagnostics; 6.1.2 Rising Demand For Minimally Invasive Advanced Screening Techniques; 6.1.3 Rising Awareness Towards Uterine Cancer; 6.1.4 Rising Importance Of Women's Health; 6.2 Restraints; 6.2.1 High Risk Complications During Diagnostic Tests; 6.2.2 Lack Of Skilled Professionals For Proper Diagnosis Of Uterine Cancer; 6.3 Opportunities; 6.3.1 Increasing Prevalence Of Uterine Cancer; 6.3.2 Rise In Adoption Of Sedentary Lifestyle; 6.3.3 Growth In Menstrual Complications; 6.4 Challenges; 6.4.1 Lack Of Diagnostic Infrastructure; 6.4.2 High Cost Of Imaging Systems
7 North America Uterine Cancer Diagnostics Market, By Diagnostic Type: 7.1 Overview; 7.2 Instrument-based; 7.2.1 Ultrasound Scanning; 7.2.1.1 Systems; 7.2.1.2 Abdominal Ultrasound Scanning; 7.2.1.3 Transvaginal Ultrasound Scanning; 7.2.1.4 Accessories; 7.2.2 Imaging Devices; 7.2.2.1 Ct/Pet (Positron Emission Tomography) Scan; 7.2.2.2 Magnetic Resonance Imaging (Mri); 7.2.2.3 Computed Tomography (Ct) Scan; 7.2.2.4 Others; 7.2.3 Tests; 7.2.3.1 Blood Tests; 7.2.3.1.1 Complete Blood Count; 7.2.3.1.2 Ca125 Marker Blood Test; 7.2.3.2 Urine Tests; 7.2.3.3 Other Tests; 7.2.4 Others; 7.3 Procedure Based; 7.3.1 Endometrial Biopsy; 7.3.2 Hysteroscopy; 7.3.3 Dilation & Curettage; 7.3.4 Cystoscopy; 7.3.5 Proctoscopy; 7.3.6 Others
8 North America Uterine Cancer Diagnostics Market, By Type: 8.1 Overview; 8.2 Endometrial Cancer; 8.2.1 Serous Adenocarcinoma; 8.2.1.1 Instrument-based; 8.2.1.1.1 Ultrasound Scanning; 8.2.1.1.2 Imaging Devices; 8.2.1.1.3 Tests; 8.2.1.1.4 Others; 8.2.1.2 Procedure-based; 8.2.1.2.1 Endometrial Biopsy; 8.2.1.2.2 Hysteroscopy; 8.2.1.2.3 Dilation & Curettage; 8.2.1.2.4 Cystoscopy; 8.2.1.2.5 Proctoscopy; 8.2.1.2.6 Others; 8.2.2 Adenosquamous Carcinoma; 8.2.2.1 Instrument-based; 8.2.2.1.1 Ultrasound Scanning; 8.2.2.1.2 Imaging Devices; 8.2.2.1.3 Tests; 8.2.2.1.4 Others; 8.2.2.2 Procedure-based; 8.2.2.2.1 Endometrial Biopsy; 8.2.2.2.2 Hysteroscopy; 8.2.2.2.3 Dilation & Curettage; 8.2.2.2.4 Cystoscopy; 8.2.2.2.5 Proctoscopy; 8.2.2.2.6 Others; 8.2.3 Uterine Carcinosarcoma; 8.2.3.1 Instrument-based; 8.2.3.1.1 Ultrasound Scanning; 8.2.3.1.2 Imaging Devices; 8.2.3.1.3 Tests; 8.2.3.1.4 Others; 8.2.3.2 Procedure-based; 8.2.3.2.1 Endometrial Biopsy; 8.2.3.2.2 Hysteroscopy; 8.2.3.2.3 Dilation & Curettage; 8.2.3.2.4 Cystoscopy; 8.2.3.2.5 Proctoscopy; 8.2.3.2.6 Others; 8.2.4 Primary Pure Squamous Cell Carcinoma Of The Endometrium; 8.2.4.1 Instrument-based; 8.2.4.1.1 Ultrasound Scanning; 8.2.4.1.2 Imaging Devices; 8.2.4.1.3 Tests; 8.2.4.1.4 Others; 8.2.4.2 Procedure-based; 8.2.4.2.1 Endometrial Biopsy; 8.2.4.2.2 Hysteroscopy; 8.2.4.2.3 Dilation & Curettage; 8.2.4.2.4 Cystoscopy; 8.2.4.2.5 Proctoscopy; 8.2.4.2.6 Others; 8.3 Uterine Sarcoma; 8.3.1 Leiomyosarcoma; 8.3.1.1 Instrument-based; 8.3.1.1.1 Ultrasound Scanning; 8.3.1.1.2 Imaging Devices; 8.3.1.1.3 Tests; 8.3.1.1.4 Others; 8.3.1.2 Procedure-based; 8.3.1.2.1 Endometrial Biopsy; 8.3.1.2.2 Hysteroscopy; 8.3.1.2.3 Dilation & Curettage; 8.3.1.2.4 Cystoscopy; 8.3.1.2.5 Proctoscopy; 8.3.1.2.6 Others; 8.3.2 Endometrial Stromal Sarcoma; 8.3.2.1 Instrument-based; 8.3.2.1.1 Ultrasound Scanning; 8.3.2.1.2 Imaging Devices; 8.3.2.1.3 Tests; 8.3.2.1.4 Others; 8.3.2.2 Procedure-based; 8.3.2.2.1 Endometrial Biopsy; 8.3.2.2.2 Hysteroscopy; 8.3.2.2.3 Dilation & Curettage; 8.3.2.2.4 Cystoscopy; 8.3.2.2.5 Proctoscopy; 8.3.2.2.6 Others; 8.3.3 Undifferentiated Sarcoma; 8.3.3.1 Instrument-based; 8.3.3.1.1 Ultrasound Scanning; 8.3.3.1.2 Imaging Devices; 8.3.3.1.3 Tests; 8.3.3.1.4 Others; 8.3.3.2 Procedure-based; 8.3.3.2.1 Endometrial Biopsy; 8.3.3.2.2 Hysteroscopy; 8.3.3.2.3 Dilation & Curettage; 8.3.3.2.4 Cystoscopy; 8.3.3.2.5 Proctoscopy; 8.3.3.2.6 Others
9 North America Uterine Cancer Diagnostics Market, By Age Group: 9.1 Overview; 9.2 >60 Years; 9.3 51-60 Years; 9.4 41-50 Years; 9.5 31-40 Years; 9.6 <30 Years
10 North America Uterine Cancer Diagnostics Market, By End User: 10.1 Overview; 10.2 Hospitals; 10.3 Diagnostic Centers; 10.4 Cancer Research Centers; 10.5 Ambulatory Surgical Centers; 10.6 Specialized Clinics; 10.7 Others
11 North America Uterine Cancer Diagnostics Market, By Distribution Channel: 11.1 Overview; 11.2 Direct Tender; 11.3 Third Party Distributors; 11.4 Others
12 North America Uterine Cancer Diagnostics Market, By Region: 12.1 North America; 12.1.1 U.S.; 12.1.2 Canada; 12.1.3 Mexico
13 North America Uterine Cancer Diagnostics Market, Company Landscape: 13.1 Company Share Analysis: North America
14 Swot Analysis
15 Company Profile: 15.1 Koninklijke Philips N.V.; 15.1.1 Company Snapshot; 15.1.2 Revenue Analysis; 15.1.3 Company Share Analysis; 15.1.4 Product Portfolio; 15.1.5 Recent Developments; 15.2 Canon Medical Systems Anz Pty Limited.; 15.2.1 Company Snapshot; 15.2.2 Company Share Analysis; 15.2.3 Product Portfolio; 15.2.4 Recent Developments; 15.3 General Electric Company; 15.3.1 Company Snapshot; 15.3.2 Revenue Analysis; 15.3.3 Company Share Analysis; 15.3.4 Product Portfolio; 15.3.5 Recent Developments; 15.4 Siemens Healthcare Gmbh; 15.4.1 Company Snapshot; 15.4.2 Revenue Analysis; 15.4.3 Company Share Analysis; 15.4.4 Product Portfolio; 15.4.5 Recent Developments; 15.5 Fujifilm Corporation; 15.5.1 Company Snapshot; 15.5.2 Revenue Analysis; 15.5.3 Company Share Analysis; 15.5.4 Product Portfolio; 15.5.5 Recent Developments; 15.6 Aed.Md; 15.6.1 Company Snapshot; 15.6.2 Product Portfolio; 15.6.3 Recent Developments; 15.7 Arquer Diagnostics Ltd; 15.7.1 Company Snapshot; 15.7.2 Product Portfolio; 15.7.3 Recent Developments; 15.8 B. Braun Se; 15.8.1 Company Snapshot; 15.8.2 Product Portfolio; 15.8.3 Recent Developments; 15.9 Esaote Spa; 15.9.1 Company Snapshot; 15.9.2 Product Portfolio; 15.9.3 Recent Developments; 15.10 F. Hoffmann-la Roche Ltd; 15.10.1 Company Snapshot; 15.10.2 Revenue Analysis; 15.10.3 Product Portfolio; 15.10.4 Recent Developments 300
List Of Tables: Table 1 North America Rate Of Endometrial Cancer (2020); Table 2 U.S. (2022); Table 3 U.K. (2019); Table 4 Germany Rate Of Endometrial Cancer (2019); Table 5 Poland Rate Of Endometrial Cancer (2020); Table 6 Singapore (2020); Table 7 Japan (2022); Table 8 India (2020); Table 9 Australia (2022); Table 10 Brazil Rate Of Endometrial Cancer (2018); Table 11 Argentina (2020); Table 12 Uae (2020); Table 13 North America Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 14 North America Instrument-based In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 15 North America Instrument-based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 16 North America Ultrasound Scanning In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 17 North America Ultrasound Scanning In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Units); Table 18 North America Systems In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 19 North America Systems In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Units); Table 20 North America Imaging Devices In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 21 North America Imaging Devices In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Units); Table 22 North America Tests In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 23 North America Blood Tests In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 24 North America Procedure Based In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 25 North America Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 26 North America Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Units); Table 27 North America Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 28 North America Endometrial Cancer In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 29 North America Endometrial Cancer In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 30 North America Serous Adenocarcinoma In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 31 North America Instrument-based In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 32 North America Procedure Based In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 33 North America Adenosquamous Carcinoma In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 34 North America Instrument-based In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 35 North America Procedure Based In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 36 North America Uterine Carcinosarcoma In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 37 North America Instrument-based In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 38 North America Procedure Based In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 39 North America Primary Pure Squamous Cell Carcinoma Of The Endometrium In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 40 North America Instrument-based In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 41 North America Procedure Based In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 42 North America Uterine Sarcoma In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 43 North America Uterine Sarcoma In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 44 North America Leiomyosarcoma In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 45 North America Instrument-based In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 46 North America Procedure Based In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 47 North America Endometrial Stromal Sarcoma In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 48 North America Instrument-based In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 49 North America Procedure Based In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 50 North America Undifferentiated Sarcoma In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 51 North America Instrument-based In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 52 North America Procedure Based In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 53 North America Uterine Cancer Diagnostics Market, By Age Group, 2021-2030 (Usd Million); Table 54 North America >60 Years In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 55 North America 51-60 Years In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 56 North America 41-50 Years In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 57 North America 31-40 Years In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 58 North America <30 Years In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 59 North America Uterine Cancer Diagnostics Market, By End User, 2021-2030 (Usd Million); Table 60 North America Hospitals In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 61 North America Diagnostic Centers In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 62 North America Cancer Research Centers In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 63 North America Ambulatory Surgical Centers In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 64 North America Specialized Clinics In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 65 North America Others In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 66 North America Uterine Cancer Diagnostics Market, By Distribution Channel, 2021-2030 (Usd Million); Table 67 North America Direct Tender In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 68 North America Third Party Distributors In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 69 North America Others In Uterine Cancer Diagnostics Market, By Region, 2021-2030 (Usd Million); Table 70 North America Uterine Cancer Diagnostics Market, By Country, 2021-2030 (Usd Million); Table 71 North America Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 72 North America Instrument-based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 73 North America Ultrasound Scanning In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 74 North America Ultrasound Scanning In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Units); Table 75 North America Ultrasound Scanning In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd); Table 76 North America Systems In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 77 North America Systems In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Volume); Table 78 North America Systems In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd); Table 79 North America Imaging Devices In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 80 North America Imaging Devices In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Units); Table 81 North America Imaging Devices In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd); Table 82 North America Tests In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 83 North America Blood Tests In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 84 North America Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 85 North America Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Volume); Table 86 North America Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd); Table 87 North America Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 88 North America Endometrial Cancer In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 89 North America Serous Adenocarcinoma In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 90 North America Instrument-based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 91 North America Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 92 North America Adenosquamous Carcinoma In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 93 North America Instrument-based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 94 North America Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 95 North America Uterine Carcinosarcoma In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 96 North America Instrument-based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 97 North America Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 98 North America Primary Pure Squamous Cell Carcinoma Of The Endometrium In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 99 North America Instrument-based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 100 North America Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 101 North America Uterine Sarcoma In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 102 North America Leiomyosarcoma In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 103 North America Instrument-based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 104 North America Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 105 North America Endometrial Stromal Sarcoma In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 106 North America Instrument-based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 107 North America Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 108 North America Undifferentiated Sarcoma In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 109 North America Instrument-based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 110 North America Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 111 North America Uterine Cancer Diagnostics Market, By Age Group, 2021-2030 (Usd Million); Table 112 North America Uterine Cancer Diagnostics Market, By End User, 2021-2030 (Usd Million); Table 113 North America Uterine Cancer Diagnostics Market, By Distribution Channel, 2021-2030 (Usd Million); Table 114 U.S. Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 115 U.S. Instrument-based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 116 U.S. Ultrasound Scanning In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 117 U.S. Ultrasound Scanning In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Units); Table 118 U.S. Ultrasound Scanning In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd); Table 119 U.S. Systems In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 120 U.S. Systems In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Volume); Table 121 U.S. Systems In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd); Table 122 U.S. Imaging Devices In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 123 U.S. Imaging Devices In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Units); Table 124 U.S. Imaging Devices In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd); Table 125 U.S. Tests In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 126 U.S. Blood Tests In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 127 U.S. Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 128 U.S. Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Volume); Table 129 U.S. Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd); Table 130 U.S. Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 131 U.S. Endometrial Cancer In Uterine Cancer Diagnostics Market, By Type, 2021-2030 (Usd Million); Table 132 U.S. Serous Adenocarcinoma In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 133 U.S. Instrument-based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 134 U.S. Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 135 U.S. Adenosquamous Carcinoma In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 136 U.S. Instrument-based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 137 U.S. Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 138 U.S. Uterine Carcinosarcoma In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 139 U.S. Instrument-based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 140 U.S. Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 141 U.S. Primary Pure Squamous Cell Carcinoma Of The Endometrium In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 142 U.S. Instrument-based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million); Table 143 U.S. Procedure Based In Uterine Cancer Diagnostics Market, By Diagnostics Type, 2021-2030 (Usd Million) 160
List Of Figures: Figure 1 North America Uterine Cancer Diagnostic Market: Segmentation; Figure 2 North America Uterine Cancer Diagnostic Market: Data Triangulation; Figure 3 North America Uterine Cancer Diagnostic Market: Droc Analysis; Figure 4 North America Uterine Cancer Diagnostic Market: North America Vs Regional Market Analysis; Figure 5 North America Uterine Cancer Diagnostic Market: Company Research Analysis; Figure 6 North America Uterine Cancer Diagnostic Market: Interview Demographics; Figure 7 North America Uterine Cancer Diagnostic Market: Market Application Coverage Grid; Figure 8 North America Uterine Cancer Diagnostic Market: Dbmr Market Position Grid; Figure 9 North America Uterine Cancer Diagnostic Market: Vendor Share Analysis; Figure 10 North America Uterine Cancer Diagnostic Market: Segmentation; Figure 11 Growing Awareness Of Uterine Cancer And Increasing Healthcare Expenditure Is Expected To Drive The Growth Of The North America Uterine Cancer Diagnostic Market From 2023 To 2030; Figure 12 Instrument Based Segment Is Expected To Account For The Largest Share Of The North America Uterine Cancer Diagnostic Market In 2023 & 2030; Figure 13 Drivers, Restraints, Opportunities, And Challenges Of The Uterine Cancer Diagnostics Market; Figure 14 North America Uterine Cancer Diagnostics Market : By Diagnostic Type, 2022; Figure 15 North America Uterine Cancer Diagnostics Market : By Diagnostic Type, 2023-2030 (Usd Million); Figure 16 North America Uterine Cancer Diagnostics Market : By Diagnostic Type, Cagr (2023-2030); Figure 17 North America Uterine Cancer Diagnostics Market : By Diagnostic Type, Lifeline Curve; Figure 18 North America Uterine Cancer Diagnostics Market: By Type, 2022; Figure 19 North America Uterine Cancer Diagnostics Market: By Type, 2023-2030 (Usd Million); Figure 20 North America Uterine Cancer Diagnostics Market: By Type, Cagr (2023-2030); Figure 21 North America Uterine Cancer Diagnostics Market: By Type, Lifeline Curve; Figure 22 North America Uterine Cancer Diagnostics Market: By Age Group, 2022; Figure 23 North America Uterine Cancer Diagnostics Market: By Age Group, 2023-2030 (Usd Million); Figure 24 North America Uterine Cancer Diagnostics Market: By Age Group, Cagr (2023-2030); Figure 25 North America Uterine Cancer Diagnostics Market: By Age Group, Lifeline Curve; Figure 26 North America Uterine Cancer Diagnostics Market : By End User, 2022; Figure 27 North America Uterine Cancer Diagnostics Market : By End User, 2023-2030 (Usd Million); Figure 28 North America Uterine Cancer Diagnostics Market : By End User, Cagr (2023-2030); Figure 29 North America Uterine Cancer Diagnostics Market : By End User, Lifeline Curve; Figure 30 North America Uterine Cancer Diagnostics Market : By Distribution Channel, 2022; Figure 31 North America Uterine Cancer Diagnostics Market : By Distribution Channel, 2023-2030 (Usd Million); Figure 32 North America Uterine Cancer Diagnostics Market : By Distribution Channel, Cagr (2023-2030); Figure 33 North America Uterine Cancer Diagnostics Market : By Distribution Channel, Lifeline Curve; Figure 34 North America Uterine Cancer Diagnostics Market: Snapshot (2022); Figure 35 North America Uterine Cancer Diagnostics Market: By Country (2022); Figure 36 North America Uterine Cancer Diagnostics Market: By Country (2023 & 2030); Figure 37 North America Uterine Cancer Diagnostics Market: By Country (2022 & 2030); Figure 38 North America Uterine Cancer Diagnostics Market: By Diagnostic Type (2023-2030); Figure 39 North America Uterine Cancer Diagnostics Market: Company Share 2022 (%) 187